Adrián Rendón
A5030982456- Tuberculosis Research and Epidemiology
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Asthma and respiratory diseases
- Fungal Infections and Studies
- COVID-19 Clinical Research Studies
- Antifungal resistance and susceptibility
- Respiratory viral infections research
- Infectious Diseases and Mycology
- Nail Diseases and Treatments
- Pharmaceutical studies and practices
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Injury Epidemiology and Prevention
- Inhalation and Respiratory Drug Delivery
- Pharmacovigilance and Adverse Drug Reactions
- Chronic Disease Management Strategies
- Global Health and Surgery
- Pediatric health and respiratory diseases
- Lung Cancer Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
Universidad Autónoma de Nuevo León
2015-2024
Hospital Universitario Dr José Eleuterio Gonzalez
2009-2024
Municipality of Medellín
2023
Istituti Clinici Scientifici Maugeri
2018-2021
Sociedad Española de Neumología y Cirugía Torácica
2021
University of Monterrey
2016-2019
United Community Center
2015
California State University, Long Beach
2014
Sistema Nacional de Investigadores
2011
Universidad Autónoma de Baja California
2009-2010
ABSTRACT We analyzed a global collection of Mycobacterium tuberculosis strains using 212 single nucleotide polymorphism (SNP) markers. SNP diversity was high (average across all SNPs, 0.19), and 96% the locus pairs were in complete linkage disequilibrium. Cluster analyses identified six deeply branching, phylogenetically distinct cluster groups (SCGs) five subgroups. The SCGs strongly associated with geographical origin M. samples birthplace human hosts. most ancestral (SCG-1) predominated...
Background. Invasive fungal diseases (IFD) caused by Cryptococcus and dimorphic fungi are associated with significant morbidity mortality. Isavuconazole (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV mouth [PO]) developed for the treatment of IFD. It displays potent activity in vitro against these pathogens this report we examine outcomes patients cryptococcosis or infections treated ISAV. Methods. The VITAL study was an open-label nonrandomized phase 3 trial conducted to...
Abstract Coronavirus disease has disrupted tuberculosis services globally. Data from 33 centers in 16 countries on 5 continents showed that attendance at was lower during the first 4 months of pandemic 2020 than for same period 2019. Resources are needed to ensure care continuity pandemic.
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) management of adverse events.The aim this prospective study was to evaluate the frequency severity events anti-tuberculosis (TB) drugs in a cohort consecutive TB patients treated with new (i.e. bedaquiline, delamanid) repurposed clofazimine, linezolid) drugs, based WHO aDSM project. Adverse were collected prospectively after attribution...
Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity mortality. The aim these clinical standards is to guide assessment, management infection (TBI) implementation TPT.
ObjectivesAlthough evidence is growing on the overall impact of COVID-19 pandemic tuberculosis (TB) services, global studies based national data are needed to better quantify extent and countries' preparedness tackle two diseases. The aim this study was compare number people with new diagnoses or recurrence TB disease, drug-resistant (DR)-TB, deaths in 2020 vs 2019 11 countries Europe, Northern America, Australia.MethodsTB managers directors reference centers selected provided agreed-upon...
Respiratory syncytial virus (RSV) is a significant global health concern and major cause of hospitalization, particularly among infants older adults. The clinical impact RSV well characterized in infants; however, many countries, the burden risk populations are overlooked. In Latin America, there limited data on epidemiology disease management Therefore, this region needs to be addressed. Here, current insights infections including those with underlying conditions, discussed. We also outline...
Coccidioidomycosis can be difficult to treat with available therapies, particularly in patients progressive or disseminated disease. Posaconazole is a new azole antifungal potent activity against Coccidioides species, the causative agent of coccidioidomycosis.Twenty chronic pulmonary nonmeningeal coccidioidomycosis were enrolled multicenter trial study safety and tolerability posaconazole therapy, efficacy as secondary end point. Patients received (400 mg/day) capsule formulation for up 6...
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. aim study is to prospectively evaluate effectiveness bedaquiline (and/or delamanid)- containing regimens a large cohort consecutive TB patients treated globally. This observational, prospective based on data collected and provided by Global Tuberculosis Network (GTN) centres analysed twice year. All (including children/adolescents) with and/or delamanid...
Adverse effects (AE) to TB treatment cause morbidity, mortality and interruption. The aim of these clinical standards is encourage best practise for the diagnosis management AE.
Thirty-seven multidrug-resistant and 13 pan-susceptible isolates of Mycobacterium tuberculosis were analysed for the diversity genotypes associated with known drug-resistance mechanisms. The obtained from patients attending a university clinic in Monterrey, Mexico. A total 25 IS6110-RFLP patterns (MDR-TB) isolates. Approximately 65% MDR-TB attributed to secondary resistance. Different drug-susceptibility seen clustered percentage resistant isoniazid (INH), rifampicin (RIF), ethambutol (EMB)...